Literatur
- 1
Worth H, Buhl R, Cegla U. et al .
Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie
zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und
Lungenemphysem (COPD).
Pneumologie.
2002;
56
704-738
- 2 Global Initiative for Chronic Obstructive Lung Disease (GOLD) .Global strategy for
the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated
2005 http://www.goldcopd.com(goldwr2005.pdf
- 3
Celli B R, MacNee W. and committee members .
Standards for the diagnosis and treatment of patients with COPD: a summary of the
ATS/ERS position paper.
Eur Respir J.
2004;
23
932-946
- 4
National Collaborating Centre for Chronic Conditions, National Institute of Clinical
Excellence (NICE) .
Chronic obstructive pulmonary disease. National clinical guideline on management of
chronic obstructive pulmonary disease in adults in primary and secondary care.
Thorax.
2004;
59 Suppl 1
1-232
- 5
Pauwels R A, Buist A S, Calverley P MA. et al .
Global strategy for the diagnosis, management, and prevention of chronic obstructive
pulmonary disease.
Am J Respir Crit Care Med.
2001;
163
1256-1276
- 6
ATS Statement .
Standards for the diagnosis and care of patients with chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
1995;
152
S77-S120
- 7
Siafakas N M, Vermeire P, Pride N B. et al .
ERS-Consensus statement. Optimal assessment and management of chronic obstructive
pulmonary disease.
Eur Respir J.
1995;
8
1388-1420
- 8
BTS .
Guidelines for the management of chronic obstructive pulmonary disease.
Thorax.
1997;
52 (Suppl 5)
S1-S28
- 9 Canadian Respiratory Review Panel .Guidelines for the treatment of chronic obstructive
pulmonary disease (COPD). Monograph 1998
- 10
Laitinen L, Koskela K. et al .
Chronic bronchitis and chronic obstructive pulmonary disease: Finnish national guidelines
for prevention and treatment 1998 - 2007.
Respir Med.
1999;
93
297-332
- 11
Lorenz W, Ollenschläger G. et al .
Das Leitlinienmanual von AWMF und ÄZQ.
ZaeFQ.
2001;
95 (Suppl. I)
41-43
- 12 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften .Erarbeitung
von Leitlinien für Diagnostik und Therapie. Methodische Empfehlungen. Abrufbar unter:
http://www.uni-duesseldorf.de/WWW/AWMF
- 13
Society for Medical Decision Making .
Committee on standardization of clinical algoritms. Proposals for clinical algorithm
standards.
Med Decis Making.
1992;
12
149-154
- 14
Report of an expert committee: Definition and diagnosis of pulmonary disease with
special reference to chronic bronchitis and emphysema.
WHO Techn Rep Ser.
1961;
213
14-19
- 15
Ciba guest symposium report: Terminology, definitions and classifications of chronic
pulmonary emphysema and related conditions.
Thorax.
1959;
14
286-299
- 16 Konietzko N, Fabel H. Weißbuch Lunge 2000. Stuttgart-New York: Thieme
- 17 Statistisches Bundesamt .Statistisches Jahrbuch, Jahrgänge 1968 - 1999. Stuttgart-Mainz:
Kohlhammer
- 18 Murray C JL, Lopez A D. The global burden of disease: A comprehensive assessment
of mortality and disability from diseases. Injuries and risk factors in 1990 and projected
to 2020. Cambridge: Harvard University Press 1996
- 19
Lopez A D, Murray C JL.
The global burden of disease, 1990 - 2020.
Nature Med.
1998;
4
1241-1243
- 20
Nowak D, Berger K, Lioppert B. et al .
Epidemiology and health economics of COPD across Europe. A Critical Analysis.
Treat Respir Med.
2006;
4
381-395
- 21 Fabel H, Konietzko N. (Hrsg) .Weißbuch Lunge. Stuttgart, New York: Thieme Verlag
2005
- 22
Rulff L K, Volmer T, Nowak D.
The economic inpact of smoking in Germany.
Eur Respir J.
2000;
16
385-390
- 23
Rychlik R, Pfeil T, Daniel D. et al .
Zur sozioökonomischen Relevanz akuter Exacerbationen der chronischen Bronchitis in
der Bundesrepublik Deutschland.
Dtsch Med Wschr.
2001;
126
353-359
- 24
Nowak D, Dietrich E S, Oberender P. et al .
Krankheitskosten von COPD in Deutschland.
Pneumologie.
2004;
58 (12)
837-844
- 25
Laurell C B, Eriksson S.
The electrophoretic alpha-1 globulin pattern of serum in alpha-1 antitrypsin deficiency.
Scand J Clin Lab Invest.
1963;
15
132-140
- 26 Orie N GM, Sluiter H J, De Vreis K. et al .Bronchitis, an international symposium. Assen,
Netherlands: Royal Vangorum 1961: 43-59
- 27
Svanes C, Omenaas E, Heuch J M. et al .
Birth characteristics and asthma symptoms in young adults: results from a population-based
cohort study in Norway.
Eur Respir J.
1998;
12
1366-1370
- 28
Todisco T, de Benedictis F M, Iannacci L. et al .
Mild prematurity and respiratory functions.
Eur J Pediatr.
1993;
152
55-58
- 29
Stein C E, Kumaran K, Fall C H. et al .
Relation of fetal growth to adult lung function in South India.
Thorax.
1997;
52
895-899
- 30
Morgan W J.
Maternal smoking and infant lung function: further evidence for an in utero effect.
Am J Respir Crit Care Med.
1998;
158
689-690
- 31 U.S. Surgeon General .The health consequences of smoking: chronic obstructive pulmonary
disease. Washington DC: U.S. Department of health and human services 1984. Publication
No. 84-50205
- 32
Leuenberger P, Schwartz J, Ackermann-Liebrich U. et al .
Passive smoking exposure in adults and chronic respiratory symptoms (SAPALDIA Study).
Swiss Study on air pollution and lung diseases in adults. SAPALDIA Team.
Am J Respir Crit Care Med.
1994;
150
1222-1228
- 33
Dayal H H, Khuder S, Sharrar R. et al .
Passive smoking in obstructive respiratory disease in an industrialized urban population.
Environ Res.
1994;
65
161-171
- 34
Holt P G.
Immune and inflammatory function in ciacutegarette smokers.
Thorax.
1987;
42
241-249
- 35
Kauffmann F, Droulet D, Lellouch J. et al .
Twelve years spirometric changes among Paris area workers.
Int J Epidemiol.
1979;
8
201-212
- 36 Niewoehner D E. Anatomic and pathophysiological correlations in COPD. In: Baum
Gl, Crapo JD, Celli BR, Karlinsky JB (eds). Textbook of pulmonary diseases. Philadelphia:
Lippincott-Raven 1998: 823-842
- 37
Chen J C, Mannino M D.
Worldwide epidemiology of chronic obstructive pulmonary disease.
Current Opin Pulmon Med.
1995;
5
93-99
- 38
Behera D, Jindal S K.
Respiratory symptoms in Indian women using domestic cooking fuels.
Chest.
1991;
100
385-388
- 39 Georgopoulos D, Anthonisen N R. Symptoms and signs of COPD. In: Cherniack NS (ed).
Chronic obstructive pulmonary disease Toronto: Saunders 1991: 357-363
- 40 Criée; C-P, Berdel D, Heise D. et al .Empfehlungen der Deutschen Atemwegsliga zur
Spirometrie. Dustri-Verlag Dr. Karl Feistle, ISBN 3-87185-364-X)
- 41
Pellegrino R, Viegi G, Brusasco V. et al .
Interpretative strategies for lung function tests.
Eur Respir J.
2005;
26
948-968
- 42
Taube M D, Lehnigk B, Paasch K. et al .
Factor analysis of changes in dyspnea and lung function parameters after bronchodilatation
in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2000;
162
216-220
- 43
O'Donnell D E, Lam M, Webb K A.
Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic
obstructive pulmonary disease.
Am J Respir Crit Care Med.
1998;
158
1557-1565
- 44
O'Donnell D E, Lam M, Webb K A.
Spirometric correlates for improvement in exercise performance after anticholinergic
therapy in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1999;
160
542-549
- 45
Marin J M, Carrizo S J, Gascon M. et al .
Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance
during the 6-minute-walk test in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
163
1395-1399
- 46
Traver G A, Cline M G, Burrows B.
Predictors of mortality in COPD.
Am Rev Respir Dis.
1979;
119
895-902
- 47
Burrows B.
The course and prognosis of different types of chronic airflow limitation in a general
population sample from Arizona: comparison with the Chicago “COPD” series.
Am Rev Respir Dis.
1989;
140
S92-S94
- 48
Seemungal T A, Donaldson G C, Bhownik A. et al .
Time course and recovery of exacerbations in patients with chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
2000;
161
1608-1613
- 49
Calverley P MA, Burge P S, Spencer S. et al .
Bronchodilator reversibility testing in chronic obstructive pulmonary disease.
Thorax.
2003;
58
659-664
- 50
Berger R, Smith D.
Effect of an inhaled metaproterenol on exercise performance in patients with stable
“fixed” airway obstruction.
Am Rev Respir Dis.
1988;
138
626-629
- 51
Casaburi R, Mahler D A, Jones P W. et al .
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary
disease.
Eur Respir J.
2002;
19
217-224
- 52
Vincken W, Noord J A von, Greefhorst A P. et al .
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.
Eur Respir J.
2002;
19
209-216
- 53
Celli B, ZuWallack R, Wang S. et al .
Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in
COPD Patients With Increased Static Lung Volumes.
Chest.
2003;
124
1743-1748
- 54
Calverley P, Pauwels R, Vestbo J. et al .
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
2003;
361
449-456
- 55
Callahan C M, Cirrus R S, Katz B P.
Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary
disease: a meta-analysis.
Ann Intern Med.
1991;
114
216-223
- 56
Kardos P, Brutsche M, Buhl R. et al .
Kombination von Asthma und COPD - häufiger als man denkt?.
Pneumologie.
2006;
60
366-372
- 57
Casanova C, Cote C, de Torres J P. et al .
Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic
Obstructive Pulmonary Disease.
Am J Respir Crit Care Med.
2005;
171
591-597
- 58
Roberts C M, Bugler J R, Melchor R. et al .
Value of pulse oximetry for long-term oxygen therapy requirement.
Eur Respir J.
1993;
6
559-562
- 59
Hughes J MB, Pride N B.
In defense of the carbon monoxide transfer coefficent Kco (TL/VA).
Eur Respir J.
2001;
17
168-174
- 60
McLean A, Warren P M, Gilooly M. et al .
Microscopic and macroscopic measurement of emphysema: relation to carbon monoxide
transfer.
Thorax.
1992;
47
14-19
- 61
Gevenois P A, de Vuyst P, de Maertelaer V. et al .
Comparison of computed density and microscopic morphometry in pulmonary emphysema.
Am J Respir Crit Care Med.
1996;
154
187-192
- 62
Gould G A, Redpath A T, Ryan M. et al .
Lung CT density correlates with measurements of airflow limitation and the diffusing
capacity.
Eur Respir J.
1991;
4
141-146
- 63
Worth H, Breuer HW M, Dorow P. et al .
Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Durchführung und Bewertung
von Belastungsuntersuchungen in der Pneumologie.
Pneumologie.
1998;
52
225-231
- 64
Thurlbeck W M, Simon G.
Radiographic appearance of the chest in emphysemas.
Am J Roentgenol.
1978;
130
429-440
- 65
Morgan M DL, Denison D M, Stricklund B.
Value of computed tomography for selecting patients with bullous emphysema.
Thorax.
1986;
41
855-862
- 66
Lehtonen J, Sutinen S, Ikaheimo M. et al .
Electrocardiographic criteria for the diagnosis of right ventricular hypertrophy verified
at autopsy.
Chest.
1988;
93
839-842
- 67
Niedermeier J, Barner A, Borst M. et al .
Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Anwendung der Echokardiographie
in der pneumologischen Diagnostik.
Pneumologie.
1998;
52
519-521
- 68
O'Donnell D E, Forkert L, Webb K A.
Evaluation of bronchodilator responses in patients with “irreversible” emphysema.
Eur Respir J.
2001;
18
914-920
- 69
Begin P, Grassino A.
Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary
disease.
Am Rev Respir Dis.
1991;
143
901-903
- 70
Baldi S, Miniati M, Bellina C R. et al .
Relationship between extent of pulmonary emphysema by high-resolution computed tomography
and lung elastic recoil in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
169
585-589
- 71
Wolkove N, Dacezman E, Colacone A. et al .
The relationship between pulmonary function and dyspnoea in obstructive lung disease.
Chest.
1989;
96
1247-1251
- 72
Connolly M C, Crowley J J, Charan N B. et al .
Reduced subjective awareness of bronchoconstriction by metacholine in elderly asthmatic
and normal subjects as measured on a simple awareness scale.
Thorax.
1992;
47
410-413
- 73
Celli B R, Cote C G, Marin J M. et al .
The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in
Chronic Obstructive Pulmonary Disease.
NEJM.
2004;
350
1005-1012
- 74
Stavem K, Sandvik L, Erikssen J.
Can Global Initiative for Chronic Obstructive Lung Disease Stage 0 provide prognostic
information on long-term mortality in men?.
Chest.
2006;
130
318-325
- 75
Vestbo J, Lange P.
Can GOLD Stage 0 Provide Information of Prognostic Value in Chronic Obstructive Pulmonary
Disease?.
Am J Respir Crit Care Med.
2002;
166
329-332
- 76
Vestbo J, Lange P.
Can GOLD Stage 0 Provide Information of Prognostic Value in Chronic Obstructive Pulmonary
Disease?.
Am J Respir Crit Care Med.
2002;
166
329-332
- 77
Weiner P, Weiner M, Azgad Y. et al .
Inhaled budesonide therapy for patients with stable COPD.
Chest.
1995;
108
1568-1571
- 78
Kardos P, Brutsche M, Buhl R. et al .
Kombination von Asthma und COPD - häufiger als man denkt?.
Pneumologie.
2006;
60 (6)
366-372
- 79
Seemugal T AR, Donaldson G C, Bhowmik A. et al .
Time Course and Recovery of Exacerbations in Patients with Chronic Obstructive Pulmonary
Disease.
Am J Respir Crit Care Med.
2000;
161
1608-1613
- 80
Schols A MWJ, Slangen J, Volorris A. et al .
Wouters. Weigth loss is a reversible factor in the prognosis of COPD.
Am J Respir Crit Care Med.
1998;
157
1791-1797
- 81
Hurst R, Donaldson G C, Wilkinson T MA. et al .
Epidemiological relationships between the common cold and exacerbation frequency in
COPD.
Eur Respir J.
2005;
26
846-852
- 82
Donaldson G C, Seemungal T AR, Bhowmik A. et al .
Relationship between exacerbation frequency and lung function decline in chronic obstructive
pulmonary disease.
Thorax.
2002;
57
847-852
- 83
Anthonisen N R, Skeans M A, Wise R A. et al .
The effects of a smoking cessation intervention on 14.5-year mortality: a randomized
clinical trial.
Ann Intern Med.
2005;
142 (4)
233-239
- 84
Thomas R.
School-based programmes for preventing smoking.
Cochrane Database Syst Rev.
2002;
(4)
CD001293
- 85
Fichtenberg C M, Glantz S A.
Effect of smoke-free workplaces on smoking behaviour: systematic review.
BMJ.
2002;
325 (7357)
188
- 86
Lovato C, Linn F, Stead L F. et al .
Impact of tobacco advertising and promotion on increasing adolescent smoking behaviours.
Cochrane Database Syst Rev.
2003;
(4)
CD003439
- 87
Wilson D H, Wakefield M A, Steven I D. et al .
“Sick of smoking” evaluation of a targeted minimal smoking cessation intervention
in general practice.
Med J Aust.
1990;
152
518-521
- 88
Britton J, Knox A.
Helping people to stop smoking: the new smoking cessation guidelines.
Thorax.
1999;
54
1-2
- 89
Kottke T E, Ballista R N, de Friese G H. et al .
Attributes of successful smoking cessation interventions in medical practise. A meta-analysis
of 39 controlled trials.
JAMA.
1988;
259
2883-2889
- 90
Ockene J K, Kristeller J, Goldberg R. et al .
Increasing the efficacy of physician deliverd smoking interventions: a randomized
controlled clinical trial.
J Gen Intern Med.
1991;
6
1-9
- 91 Fiore M C, Bailey W C, Cohen S J. Smoking cessation: information for specialists.
U.S. department of health and human services. Public health service. Agency for health
care policy and research and centers for disease control and prevention. Rockville.
M.D. AHCPR Publication No. 96-0694 1996
- 92
The tobacco use and dependence clinical practice guideline panel, staff, and consortium
repesentatives. A clinical practice guideline for treating tobacco use and dependence.
JAMA.
2000;
83
3244-3254
- 93 American Medical Association .Guidelines for the diagnosis and treatment of nicotine
dependence. How to help patients stop smoking. Washington D.C.: American Medical Association
1994
- 94 Glynn T J, Manley M W. How to help your patients stop smoking. A national cancer
institute manual for physicians. U.S. Department of health and human service, public
health service. National institutes of health. National Cancer Institute, Bethesda.
M.D. NIH Publication 90-3064 1990
- 95
Anthonisen N R, Connett J E, Kiley J P. et al .
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator
on the rate of decline of FEV1: The Lung Health Study.
JAMA.
1994;
272
1497-1505
- 96 Arzneimittelkommission der Deutschen Ärzteschaft .Empfehlungen zur Therapie der
Tabakabhängigkeit. Köln: AVP-Reihe 2001
- 97
Jorenby R E, Leischow S J, Nides M A. et al .
A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking
cessation.
N Engl J Med.
1999;
340
685-691
- 98
Tashkin D P, Kanner R J, Buist S. et al .
Smoking cessation in patients with chronic obstructive pulmonary disease: a double
blind, placebo-controlled randomised trial.
Lancet.
2001;
357
1571-1575
- 99 WHO .Tobacco free initiative: Policies for public Health: www.who//int/toh/world
notto-bacco 99.
- 100 Fiore M C, Bailey W C, Cohen S J. et al .Treating tobacco use as dispendence :
A clinical practical guideline. Rockville, M.D. US Dept Health and Human Services.
A. public health service report 2000
- 101 Schwartz J L. Review and evalution of smoking cessation methods: United States
and Canada, 1978 - 1985. Bethesda, M.D.: National Institute of Health. NIH publication
87-2940 1987
- 102
Fiore M C, Smith S S, Jorenby D E. et al .
The effectiveness of the nicotine patch for smoking cessation. A meta-analysis.
JAMA.
1994;
271
1940-1947
- 103
Sachs D E, Benowitz N L.
Individual medical treatment for tobacco dependence [editorial; comment].
Eur Respir J.
1996;
9
629-631
- 104
Murray R P, Connett J E, Rand C S. et al .
Anthonisen. Persistence of the effect of the Lung Health Study (LHS) smoking intervention
over eleven years.
Prev Med.
2002;
35 (4)
314-319
- 105 Bundesversicherungsanstalt für Angestellte (BfA) .Rehabilitationsbedürftigkeit
und Indikationsübergreifende Problembereiche - Leitlinien für den Beratungsärztlichen
Dienst der BfA 2002: http://www.bfa.de/nn 5910/de/Inhalt/Publikationen/Sonstige/Infos
20f C3 BCr 20 C3 84rzte Dokumente/Reha Bed C3 Bcrftigkeit 20 2F 20 Indiaktions C3
Bcbergreifend.html,.
- 106
Eisner M D, Balmes J, Yelin E H. et al .
Directly measured secondhand smoke exposure and COPD health outcomes.
BMC Pulm Med 2006Jun.
6;
6
12
- 107 Berufsgenossenschaftlicher Grundsatz für arbeitsmedizinische Vorsorgeuntersuchungen
„G 23 - Obstruktive Atemwegserkrankungen”. Hrsg.: Hauptverband der gewerblichen Berufsgenossenschaften,
St. Augustin
- 108
Nichol K, Margolis L, Wourenma J. et al .
The efficacy and cost effectiveness of vaccination against influenza among elderley
persons living in the community.
N Engl J Med.
1994;
331
778-784
- 109
Hak E, Essen G A van, Buskens E. et al .
Is immunising all patients with chronic lung disease in the community against influenza
cost effective? Evidence from a general based clinical prospective cohort study in
Utrecht. The Netherlands.
J Epidemiol Community Health.
1998;
52
120-125
- 110
Peters P H.
Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail
older population.
J Am Geriatr Soc.
2001;
49 (8)
1025-1031
- 111
Hayden F G, Belshe R, Villanueva C. et al .
Management of influenza in households: a prospective, randomized comparison of oseltamivir
treatment with or without postexposure prophylaxis.
J Infect Dis.
2004;
189 (3)
440-449
- 112
Simberkoff M S, Cross A P, Al-Ibrahim M. et al .
Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration
Cooperative Study.
N Engl J Med.
1986;
315
1318-1327
- 113
Williams J HJ, Moser K M.
Pneumococcal vaccine and patients with chronic lung disease.
Ann Intern Med.
1986;
104
106-109
- 114
Christenson B, Lundbergh P, Hedlund J. et al .
Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines
in adults aged 65 years or older: a prospective study.
Lancet.
2001;
357
1008-1011
- 115
Davis A L, Aranda P, Schiffman G. et al .
Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic
obstructive pulmonary disease. A pilot study.
Chest.
1994;
92
204-212
- 116
Schaberg T.
Pneumokokkenschutzimpfung.
Pneumologie.
2001;
55
543-545
- 117
Ständige Impfkommission am Robert Koch-Institut (STIKO).
Epidemiologisches Bulletin des RKI.
2001;
28
203-218
- 118
Pauwels R A, Lofdahl C G, Laitinen L A. et al .
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive
pulmonary disease who continue smoking.
N Engl J Med.
1999;
340
1948-1953
- 119
Vestbo J, Sorensen T, Langer P. et al .
Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
1999;
355
1819-1823
- 120
Burge P S, Calverley M A, Jones P W. et al .
Randomised, placebo-controlled study of fluticasone proprionate in patients with moderate
to severe chronic obstructive pulmonary disease; the Isolde trial.
Br Med J.
2000;
320
1297-1303
- 121
The Lung Health Study Research Group .
Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive
pulmonary disease.
N Engl J Med.
2000;
343
1902-1909
- 122
Schayck C P van, Dompeling E, Heerwaarden C LA van. et al .
Bronchodilator treatment in modern asthma or chronic bronchitis. Continuous or on
demand. A randomised controlled study.
BMJ.
1991;
303
1426-1431
- 123
Voshaar T, App E M, Berdel D. et al .
Empfehlungen für die Auswahl von Inhalationssystemen für die Medikamentenverabreichung.
Pneumologie.
2001;
55
579-586
- 124
Dahl R, Greefhorst L A, Nowak D. et al .
Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
2001;
164
778-784
- 125
Mahler D A, Donohue J F, Barbee R A. et al .
Efficacy of salmeterol xinafoate in the treatment of COPD.
Chest.
1999;
115
957-965
- 126
Karpel J P, Pesin J, Greenberg D. et al .
A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute
exazerbations of COPD.
Chest.
1990;
98
835-839
- 127
Patrick D M, Dales R E, Stark R M. et al .
Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium
to usual therapy.
Chest.
1990;
98
295-297
- 128
Braun S R, Mc Kenzie W N, Copeland C. et al .
A comparison of the effect of ipratropium and albuterol in the treatment of chronic
airways disease.
Arch Intern Med.
1989;
149
544-547
- 129
Tashkin D P, Ashutosh K, Bleeker E R. et al .
Comparison of the anticholinergic bronchodilator ipratropiumbromide with metaproterenol
in chronic obstructive pulmonary disease: a multicenter study.
Am J Med.
1986;
81 (Suppl. 5a)
1411-1419
- 130
COMBIVENT Inhalation Aerosol Study Group .
In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol
is more effective than either agent alone: an 85-day multicenter trial.
Chest.
1994;
105
1411-1419
- 131
Rennard S I.
Extended bronchodilator treatment in chronich obstructive pulmonary disease.
European Respiratory Review.
1996;
6
282-286
- 132
Barnes P J.
The pharmacological properties of tiotropium.
Chest.
2000;
117
63S-66S
- 133
Calverley P MA.
The future of tiotropium.
Chest.
2000;
117
67S-69S
- 134
Noord J A van, Aumann J L, Janssens E. et al .
Effects of tiotropium with and without formoterol on airflow obstruction and resting
hyperinflation in patients with COPD.
Chest.
2006 Mar;
129 (3)
509-517
- 135
O'Donnell D E, Fluge T, Hamilton A. et al .
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.
Eur Respir J.
2004;
23
832-840
- 136
Niewoehner D E, Rice K, Cote C. et al .
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium,
a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Ann Intern Med.
2005;
143
317-326
- 137
Dusser D, Bravo M L, Iacono P.
The effect of tiotropium on exacerbations and airflow in patients with COPD.
Eur Respir J.
2006;
27
547-555
- 138
Casaburi R, Kukafka D, Cooper C B. et al .
Improvement in exercise tolerance with the combination of tiotropium and pulmonary
rehabilitation in patients with COPD.
Chest.
2005;
127
809-817
- 139
Brusasco V, Hodder R, Miravitlles M. et al .
Health outcomes following treatment for six months with once daily tiotropium compared
with twice daily salmeterol in patients with COPD.
Thorax.
2003 May;
58 (5)
399-404, Erratum in: Thorax 2005 Feb; 60 (2): 105
- 140
Campbell M, Eliraz A, Johannson G. et al .
Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary
disease.
Respiratory medicine.
2006;
99
1511-1520
- 141
Nisar M, Earis J E, Pearson M G. et al .
Acute bronchodilator trials in chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1992;
146
555-559
- 142
Ulrik C S.
Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive
pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover
study.
Thorax.
1995;
50
750-754
- 143
Grove A, Lipworth B J, Reid P. et al .
Effects of regular salmeterol on lung function and exercise capacity in patients with
chronic obstructive airways disease.
Thorax.
1996;
51
689-693
- 144
Boyd G, Mirice A H, Pounsford J G. et al .
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease
(COPD).
Eur Respir J.
1997;
10
815-821
- 145
Maesen B LP, Wedermann C JJ, Duarkens V AM. et al .
Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary
disease.
Eur Respir J.
1999;
13
1103-1108
- 146
O'Donnell D E, Voduc N, Fitzpatrick M. et al .
Effect of salmeterol on the ventilatory response to exercise in chronic obstructive
pulmonary disease.
Eur Respir J.
2004;
24
86-94
- 147
Jones P W, Bosh T K.
Quality of life changes in COPD patients treated with salmeterol.
Am J Respir Crit Care Med.
1997;
155
1283-1289
- 148
Peach H, Pathy M S.
Follow-up study of disability among elderly patients discharged from hospital with
exacerbations of chronic bronchitis.
Thorax.
1981;
36
585-589
- 149
Cazzola M, Imperatore F, Salzillo A. et al .
Cardiac effects of formoterol and salmeterol in patients suffering from COPD with
preexisting cardiac arrhythmia.
Chest.
1998;
114
411-415
- 150
Murciano D, Auclair M-A, Pariente R. et al .
A randomized controlled trial of theophylline in patients with severe chronic obstructive
pulmonary disease.
N Engl J Med.
1989;
320
1512-1525
- 151
McKay S E, Howie C A, Thomson A H. et al .
Value of theophylline treatment in patients handicapped by chronic obstructive pulmonary
disease.
Thorax.
1993;
48
227-232
- 152
Mulloy E, McNicholas W T.
Theophylline improves gas exchange during rest, exercise and sleep in severe chronic
obstructive pulmonary disease.
Am Rev Respir Dis.
1993;
148
1030-1036
- 153
Evans W W.
Plasma theophylline concentrations, six minute walking distances and breathlessness
in patients with chronic airflow obstruction.
BMJ.
1984;
289
1649-1651
- 154
Cooper C B, Davidson A C, Cameron I R.
Aminophylline, respiratory muscle strength and exercise tolerance in chronic obstructive
airway disease.
Clin Respir Physiol.
1987;
23
15-22
- 155
Murciano D, Aubier M, Lecolguic Y. et al .
The effects of theophylline on diaphragmatic strength an exercise tolerance in patients
with chronic obstructive pulmonary disease.
N Engl J Med.
1984;
322
349-353
- 156
Williamson B H, Milligan C, Griffiths K. et al .
Thompson. An assessment of major and minor side effects of theophylline.
Aust NZ J Med.
1988;
19
539
- 157
Kirsten D, Wegner R E, Jörres R A. et al .
Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.
Chest.
1993;
104
1101-1107
- 158
The COMBIVENT Inhalation Solution Study Group .
Routine nebulized ipratropium and albuterol together are better than either alone
in COPD.
Chest.
1997;
112
1514-1521
- 159
Taylor D R, Buick B, Kinney C. et al .
The efficacy of orally administered theophylline, inhaled salbutamol and a combination
of the two as chronic therapy in the management of chronic bronchitis with reversible
airflow obstruction.
Am J Respir Dis.
1985;
131
747-751
- 160
Friedman M, Serby C, Menjoge S. et al .
Pharmaeconomic evaluation of a combination of ipratropium plus albuterol compared
with ipratropium alone and albuterol alopne in COPD.
Chest.
1999;
115
635-641
- 161
D'Urzo A D, de Salvo M C, Ramirez-Rivera A. et al .
In patients with COPD, treatment with a combination of formoterol and ipratropium
is more effective than a combination of salbutamol and ipratropium.
Chest.
2001;
119
1347-1356
- 162
Guyatt G H, Townsend M, Pugsley S O. et al .
Bronchodilators in chronic air-flow limitation: effects on airway function, exercise
capacity and quality of life.
Am Rev Respir Dis.
1987;
135
1069-1074
- 163
Noord J A van, Aumann J-L, Janssens E. et al .
Comparison of tiotropium once daily, formoterol twice daily and both combined once
daily in patients with COPD.
Eur Respir J.
2005;
26
214-222
- 164
O'Driscoll B R, Kay E A, Taylor R J. et al .
A long-term prospective assessment of home nebulizer treatment.
Respir Med.
1992;
S6
317-325
- 165
Gan W Q, Man S FP, Sin D D.
Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive
pulmonary disease: a systematic review and a meta-analysis.
BMC Pulmonary Medicine.
2005;
5
3
- 166
Senderovitz T, Vestbo J, Frandsen J. et al .
Steroid reversibility test followed by inhaled budesonide or placebo in outpatients
with stable chronic obstructive pulmonary disease. The Danish Society or Respiratory
Medicine.
Respir Med.
1999;
93
715-718
- 167
Rice K L, Rubins J B, Lebhahn F. et al .
Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized
trial.
Am J Respir Crit Care Med.
2000;
162
174-178
- 168
Calverley P M, Boonsawat W, Cseke Z. et al .
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary
disease.
Eur Respir J.
2003;
22
912-919
- 169
Szafranski W, Cukier A, Ramirez A. et al .
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive
pulmonary disease.
Eur Respir J.
2003;
21
74-81
- 170
Wouters E F, Postma D S, Fokkens B. et al .
Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment
in patients with COPD causes immediate and sustained disease deterioration: a randomized
controlled trial.
Thorax.
2005;
60
480-487
- 171
Valk P van der, Monninkhof E, Palen J van der. et al .
Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive
pulmonary disease: the COPE study.
Am J Respir Crit Care Med.
2002;
166
1358-1363
- 172
Kardos P, Wencker M, Glaab T. et al .
Impact of salmeterol/fluticasone versus salmeterol on exacerbations in severe chronic
obstructive pulmonary disease.
Am J Respir Crit Care Med.
2007;
175
144-149
- 173
Decramer M, Lacquet L M, Fagard R. et al .
Corticosteroids contribute to muscle weakness in chronic airflow obstruction.
Am J Respir Crit Care Med.
1994;
150
11-16
- 174
Decramer M, Stas K J.
Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic
obstructive pulmonary disease or asthma.
Am J Respir Dis.
1992;
146
800-802
- 175
Schols A MWJ, Wesseling G, Keser A DM. et al .
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids.
Eur Respir J.
2001;
17
337-342
- 176
Mahler D A, Wire P, Horstmann D. et al .
Effectiveness of fluticasone propionate and salmeterol combination delivered via the
diskus device in the treatment of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2002;
166
1084-1091
- 177
Hanania N A, Darken P, Horstman D. et al .
The efficacy and safety of fluticasone propionate (250 micro g)/salmeterol (50 micro
g) combined in the diskus inhaler for the treatment of COPD.
Chest.
2003;
124
834-843
- 178
Dal Negro R, Pomari C, Tognella S. et al .
Salmeterol & fluticasone 50 micro g/250 microg bid in combination provides a better
long-term control than salmeterol 50 micro g bid alone and placebo in COPD patients
already treated with theophylinne.
Pulmonary Pharmacology and Therapeutics.
2003;
16
241-246
- 179
Maltais F, Hamilton A, Marciniuk D. et al .
Improvement in symptom-limited exercise performance over 8 h in pateints with COPD.
Chest.
2005;
128
1168-1178
- 180
Weiner P, Magadle R, Berar-Yanay N. et al .
The cumulatie effect of long-acting bronchodilators, exercise,and inspiratory muscle
training in the perception of dyspnea in patients with advanced COPD.
Chest.
2000;
118
672-678
- 181
Liesker J JW, De Velde V van, Meysman M. et al .
Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients
with COPD.
Respir Med.
2002;
96
559-566
- 182
Boyd G, Morice A H, Pounsford J C. et al .
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease
(COPD).
Eur Respir J.
1997;
10
815-821
- 183
Rennard St I, Anderson W, ZuWallack R. et al .
Use of long-acting inhaled beta2-adrenergic agonist Salmeterol xinafoate, in patients wirh chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
2001;
163
1087-1092
- 184
Man W DC, Mustfa N, Nikoletou D. et al .
Effecr of Salmeterol on respiratory muscle activity during exercise in poorly reversible
COPD.
Thorax.
2004;
59
471-476
- 185
Aalbers R, Ayres J, Backer V. et al .
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled,
3-month trial.
Eur Respir J.
2002;
19
936-943
- 186
Wadbo M, Löfdahl C-G, Larsson K. et al .
Effects of formoterol and ipratropiumbromide in COPD: a 3-month placebo-controlled
study.
Eur Respir J.
2002;
20
1138-1146
- 187
Grassi C. and the multicenter Study Group .
Longterm oral acetylcysteine in chronic bronchitis. A double blind controlled study.
Eur J Respir Dis.
1980;
61 (Suppl. 111)
93-108
- 188
Boman G, Bäcker U, Larsson S. et al .
Oral acetylcysteine reduces exacerbation rate in chronic bronchitis. Report of a trial
organized by the Swedish Society for Pulmonary Diseases.
Eur J Respir Dis.
1983;
64
405-415
- 189
Jackson M, Barnes J, Cooksey P.
Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: A
double-blind placebo-controlled study.
J Int Med Res.
1984;
12
198-205
- 190
McGavin C R. and the British Thoracic Society Research Committee .
Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and
severe airway obstruction.
Thorax.
1985;
40
832-835
- 191
Meister R.
Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer
Bronchitis. Eine doppelblinde-plazebokontrollierte Studie.
Forum Prakt Allg Arzt.
1986;
25
18-22
- 192
Parr G D, Huitson A.
Oral fabrol (oral N-acetylcysteine) in chronic bronchitis.
Br J Dis Chest.
1987;
81
341-348
- 193
Rasmussen J B, Glennow C.
Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release
tablets in patients with chronic bronchitis.
Eur Respir J.
1988;
1
351-355
- 194
Hansen N CG, Skriver A, Brorsen-Ries L. et al .
Orally administered N-acetylcysteine may improve general well-being in patients with
mild chronic bronchitis.
Respir Med.
1994;
88
531-535
- 195
Pela R, Calcagni A M, Subiaco S. et al .
N-ace-tylcysteine reduces the exacerbation rate in patients with moderate to severe
COPD.
Respiration.
1999;
66
495-500
- 196
Grandjean E M, Berthet P, Ruffmann R. et al .
Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A
metaanalysis of published double blind, placebo-controlled clinical trials.
Clin Therapeutics.
2000;
22
209-221
- 197
Stey C, Steuer J, Bachmann S. et al .
The effect of oral N-ace-tylcysteine in chronic bronchitis - a quantitative systematic
review.
Eur Respir J.
1999;
14 (Suppl. 30)
381s
- 198
Poole P J, Black P N.
Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease.
BMJ.
2001;
322
1-6
- 199
Olivieri D, Zavattini G, Tomasini G. et al .
Ambroxol for the prevention of chronic bronchitis exazerbations: long term multicenter
trial.
Respiration.
1987;
51 (Suppl. 1)
42-51
- 200
Decramer N, Rutten-van Molken M, Dekhuijzen P N. et al .
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis
Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial.
Lancet.
2005;
365
1552-1560
- 201
Collet J P, Shapiro S, Ernst P. et al .
Effect of an immunostimulating agent on acute exacerbations and hospitalizations in
COPD patients.
Am J Respir Crit Care Med.
1997;
156
1719-1724
- 202
Li J, Zheng H P, Yuan J P. et al .
Protective effect of a bacterial extract against acute exacerbations in patients with
chronic bronchitis accompanied by chronic obstructive pulmonary disease.
Chin Med J.
2004;
173
4164-4170
- 203
Anthonisen N R.
Editoral. OM-85BV for COPD.
Am J Respir Crit Care Med.
1997;
156
1713-1714
- 204
Irwin R S, Boulet L P, Cloutier M M. et al .
Managing cough as a defense mechanism and as a symptom: a consensus panel report of
the American College of Chest Physicans.
Chest.
1998;
114
133S-181S
- 205
Bardsley P A, Howard P, DeBacker W. et al .
Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive
airways disease.
Eur Respir J.
1991;
4
308-310
- 206
Watanabe S, Kanner R E, Cutillo A G. et al .
Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive
pulmonary disease.
Am J Respir Dis.
1989;
140
1269-1273
- 207
Winkelmann B R, Kullmer T H, Kneissl D G. et al .
Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive
pulmonary disease.
Chest.
block;
105
1383-1391
- 208
Eiser N, Denman W T, West C. et al .
Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the “pink puffer”
syndrome.
Eur Respir J.
1991;
4
926-931
- 209
Young I H, Daviskas E, Keena V A.
Effect of low dose nebulised morphine on exercise endurance in patients with chronic
lung disease.
Thorax.
1989;
44
387-390
- 210
Rice K L, Kronenberg R S, Hedemark L L. et al .
Effects of chronic administration of codeine and promethazine on breathlessness and
exercise tolerance in patients with chronic airflow obstruction.
Br J Dis Chest.
1987;
81
287-292
- 211
Woodcock A A, Gross E R, Gellert A A. et al .
Effects of dihyrocodeine, alcohol and caffeine on breathlessness and exercise tolerance
in patients with chronic obstructive lung disease and normal blood gases.
N Engl J Med.
1981;
305
1611-1616
- 212
Poole P J, Veale A G, Black P N.
The effect of sustained release morphine on breathlessness and quality of life in
severe chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1998;
157
1877-1880
- 213
Schönhofer B, Suchi S, Haidl P. et al .
Eine Epidemiologie zum Stellenwert von oral appliziertem Morphium als Therapieform
des schwergradigen Lungenemphysems vom Pink-Puffer-Typ.
Med Klin.
2001;
96
325-330
- 214
Alpha-1-Antitrypsin Deficiency Registry Group .
Survival and FEV1 decline in individuals with severe deficiency of a1-antitrypsin.
Am J Respir Crit Care Med.
1998;
158
49-59
- 215
Seersholm N, Kokjensen A.
Clinical features and prognosis of life time non-smokers with severe a1-antitrypsin
deficiency.
Thorax.
1998;
53
265-268
- 216
Wencker M, Banik N, Buhl R.
Long-term treatment of a1-antitrypsin deficiency related pulmonary emphysema with
human a1-antitrypsin.
Eur Respir J.
1998;
11
428-433
- 217
Incalci R A, Caradonna P, Ranieri P. et al .
Correlates of osteoporosis in chronic obstructive pulmonary disease.
Respir Med.
2000;
94
1079-1084
- 218
American College of Rheumatology ad hoc Committee on glucocorticoid-induced osteoporosis.
Recommendations for the prevention and treatment of glucocortocoid-induced osteoporosis.
Arthritis Rheumatism.
2001;
44
1496-1503
- 219
Chavannes N, Vollenberg J J, Schayck C P van. et al .
Effects of physical activity in mild to moderate COPD: a systematic review.
Br J Gen Pract.
2002;
52
547-548
- 220
Berry M J, Rejeski W J, Adair N E. et al .
Exercise rehabilitation and chronic obstructive pulmonary disease stage.
Am J Respir Crit Care Med.
1999;
160
1248-1253
- 221
ACCP/AAC/VPR Pulmonary Rehabilitation Guidelines Panel .
Pulmonary Rehabilitation.
Chest.
1997;
112
1363-1395
- 222
American Thoracic Society .
Pulmonary Rehabilitation 1999.
Am J Respir Crit Care Med.
block;
159
1666-1682
- 223
Lacasse Y, Wong E, Guyatt G H. et al .
Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease.
Lancet.
1996;
348
1115-1119
- 224
Worth H, Meyer A, Folgering H. et al .
Empfehlungen der Deutschen Atemwegsliga zum Sport und körperlichen Training bei Patienten
mit obstruktiven Atemwegserkrankungen.
Pneumologie.
2000;
54
61-67
- 225
Ringbaek T J, Broendum E, Hemmingsen L. et al .
Rehabilitation of patients with chronic obstructive pulmonary disease.
Exercise twice a week is not sufficient! Respir Med.
2000;
94
150-154
- 226
Puente-Maestu L, Sanz M L, Sanz P. et al .
Comparison of effects of supervised versus self-monitored training programmes in patients
with chronic obstructive pulmonary disease.
Eur Respir J.
2000;
5
517-525
- 227
Lacasse Y, Brosseau L, Milne S. et al .
Pulmonary rehabilitation for chronic obstructive pulmonary disease.
Cochrane Database Syst Rev.
2002;
CD003793
- 228
Salman G F, Mosier M C, Beasley B W. et al .
Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis
of randomized controlled trials.
J Gen Intern Med.
2003;
18
213-221
- 229
Puhan M A, Schunemann H J, Frey M. et al .
How should COPD patients exercise during respiratory rehabilitation? Comparison of
exercise modalities and intensities to treat skeletal muscle dysfunction.
Thorax.
2005;
60
367-375
- 230
American Thoracic Society/European Respiratory Society .
Statement on Pulmonary Rehabilitation.
Am J Respir Crit Care Med.
2006;
173
1390-1413
- 231
Bernhard S, Whittom F, Leblanc P. et al .
Aerobic and strength training in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1999;
159
896-901
- 232
Belman M J, Botnick W C, Nathan S D. et al .
Ventilatory load characteristics during ventilatory muscle training.
Am J Respir Crit Care Med.
1994;
149
925-929
- 233
Griffiths T L, Burr M L, Campbell I A. et al .
Results at 1 year of out-patient multidisciplinary pulmonary rehabilitation.
Lancet.
2000;
355
362-368
- 234
Foglio K, Bianchi L, Bruletti G. et al .
Long-term effectiveness of pulmonary rehabilitation in patients with chronic airways
obstruction.
Eur Respir J.
1999;
13
125-132
- 235
Young P, Dewse M, Ferguson W. et al .
Improvements in outcomes for chronic obstructive pulmonary disease (COPD) attributable
to a hospital-based respiratory rehabilitation programme.
Aus NZ J Med.
1999;
29
59-65
- 236
Dhein Y, Birkenmaier A, Otte B. et al .
Evaluation of a structured education programme (AFBE) for patients with mild to moderate
COPD under outpatient conditions.
Am J Respir Crit Care Med.
2002;
165
A420
- 237
Worth H, Dhein Y.
Does patient education modify behaviour in the management of COPD?.
Patient Educ Couns.
2004;
52
267-270
- 238
Bourbeau J, Julien M, Maltais F. et al .
Reduction of hospital utilization in patients with chronic obstructive pulmonary disease:
a disease-specific self-management intervention.
Arch Intern Med.
2003;
163
585-591
- 239
Gadoury M A, Schwarztmann K, Rouleau M. et al .
Self-management reduces both short- and long-term hospitalisation in COPD.
Eur Respir J.
2005;
26
853-857
- 240
Steier J, Petro W.
Physikalische Therapie bei COPD - Evidence based Medicine?.
Pneumologie.
2002;
556
388-396
- 241 Bekkering G E, Hendriks H JM, Chadwick-Straver R VM. et al .Clinical practice
guidelines for physical therapy in patients with chronic obstructive pulmonary disease. 2003
Available from. http://www.fysionet.nl, V-03/2003/US
- 242
Murray J F.
The ketch-up bottle method.
N Engl J Med.
1979;
300
1155-1157
- 243
Anthonisen P, Ries P, Sogaard-Andersen T.
The value of lung physiotherapy in the treatment of acute exacerbations in chronic
bronchitis.
Acta Med Scand.
1964;
145
715-719
- 244
Graham W, Bradley G A.
Efficacy of chest physiotherapy and intermittent positive-pressure breathing in the
resolution of pneumonia.
N Engl J Med.
1978;
299
624-627
- 245
King M, Philips D M, Gron D. et al .
Enhanced tracheal mucus clearance with high frequency chest wall percussion.
Am Rev Respir Dis.
1983;
128
511-515
- 246
Pryer J A.
Physiotherapy for airway clearance in adults.
Eur Respir J.
1999;
14
1418-1424
- 247
Hietpas B G, Roth R D, Jensen M W.
Huff coughing and airway patency.
Respir Care.
1979;
24
710-713
- 248
Cegla U H, Petzow A.
Physiotherapie mit dem VRP1 bei chronisch obstruktiven Atemwegserkrankungen - Ergebnisse
einer multizentrischen Vergleichsstudie.
Pneumologie.
1993;
47
636-639
- 249
App E M, Wunderlich M O, Lohse P. et al .
Oszillierende Physiotherapie bei Bronchialerkrankungen - rheologischer- und antientzündlicher
Effekt.
Pneumologie.
1999;
53
1-12
- 250
Cegla U H, Bautz M, Fröde G. et al .
Physiotherapie bei Patienten mit COPD und tracheobronchialer Instabilität - Vergleich
zweier oszillierender PEP-Systeme (RC-Cornet, VRP1-Destin).
Pneumologie.
1997;
51
129-136
- 251
King M, Feng W, Deng W W. et al .
Short-term efficacy of RC-Cornet in decreasing cohessiveness of sputum in COPD-patients.
Chest.
1998;
225
318
- 252
Engelken M PKJ, Schols A MWJ, Baker W C. et al .
Nutritional depletion in relation to respiratory and peripheral muscle function in
outpatients with COPD.
Eur Respir J.
1994;
7
1793-1797
- 253
Schols A MWJ, Soeters P B, Dingemans A MC. et al .
Prevalence and characteristics of nutritional depletion in patients with stable COPD
eligible for pulmonary rehabilitation.
Am Rev Respir Dis.
1993;
147
1187-1196
- 254
Wilson D O, Rogers R M, Wright E C. et al .
Body weight in chronic obstructive pulmonary disease. The National Institutes of Health
intermittend positive-pressure breathing trial.
Am Rev Respir Dis.
1989;
139
1435-1438
- 255
Wouters E FM, Schols A MWJ.
Nutritional depletion in COPD.
Eur Respir Rev.
1997;
7
60-65
- 256
Fitting J W.
Nutritional support in chronic obstructive lung disease.
Thorax.
1992;
47
141-143
- 257
Hunter A BN, Carey M A, Lorch H W.
The nutritional status of patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1985;
132
1347-1365
- 258
Gray-Donald K, Gibbone L, Shapiro S H. et al .
Nutritional status and mortality in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1996;
153
961-966
- 259
Baarends E M, Schols A MWJ, Mostert R. et al .
Peak exercise in relation to tissue depletion in patients with chronic obstructive
pulmonary disease.
Eur Respir J.
1997;
10
2807-2813
- 260
Shoup R, Dalshy G, Warner G. et al .
Body composition and health related quality of life in patients with chronic obstructive
airways disease.
Eur Respir J.
1997;
10
1576-1580
- 261
Wijkstra P J, Atena R van, Kraan J. et al .
Quality of life in patients with chronic obstructive pulmonary disease improve after
rehabilitation at home.
Eur Respir J.
1994;
7
307-311
- 262
Ferreira I M, Brooks D, Lacasse Y. et al .
Nutritional supplementation for stable chronic obstructive pulmonary disease.
Cochrane Database Syst Rev.
2005;
block
CD000998
- 263
Efthimiou J, Fleming J, Gomes C. et al .
The effect of supple-mentary oral nutrition in poorly nourished patients with chronic
obstructive pulmonary disease.
Am Rev Respir Dis.
1988;
137
1075-1082
- 264
Rogers R M, Donahue M, Constantino J.
Physiologic effects of oral supplemental feeding in malnourished patients with chronic
obstructive pulmonary disease patients.
Am Rev Respir Dis.
block;
145
1511-1597
- 265
Whittaker J S, Buckley C F, Road J D.
The effects of re-feeding on peripheral and respiratory muscle function in malnourished
chronic obstructive pulmonary disease patients.
Am Rev Respir Dis.
1990;
142
283-288
- 266
Schols A M, Soeters P B, Mostert R. et al .
Physiologic effects of nutritional support and anabolic steroids in patients with
chronic obstructive pulmonary disease. A placebo-controlled randomized trial.
Am J Respir Crit Care Med.
1995;
152
1268-1274, 204
- 267
Creutzberg E C, Wouters E F, Mistert R. et al .
A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind,
placebo-controlled, randomized trial.
Chest.
2003;
124
1733-1742
- 268
Casaburi R, Bhasin S, Cosentino L. et al .
Effects of testestorone and resistance training in men with chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
2004;
170
870-878
- 269
Bergmann K C, Fischer J, Schmitz M. et al .
Die stationäre Rehabilitation für Erwachsene. Zielsetzung - Diagnostik und therapeutische
Standards - Forschungsbedarf.
Pneumologie.
1997;
51
523-532
- 270
Donner C F, Muir J F.
Selection criteria and programmes for pulmonary rehabilitation in COPD patients. Rehabilitation
and chronic care scientific group of the european respiratory society.
Eur Respir J.
1997;
10
744-757
- 271
British Thoracic Society. Pulmonary rehabilitation.
Thorax.
2001;
56
827-834
- 272
Young P, Dewse M, Fergusson W. et al .
Respiratory rehabilitation in chronic obstructive pulmonary disease: predictors of
non-adherence.
Eur Respir J.
1999;
13
867-872
- 273
Connors A F, Dawson N V, Thomas C. et al .
Outcomes following acute exacerbation of severe chronic obstructive lung disease.
The SUPPORT investigators (Study to Unterstand Prognoses and Preferences for Outcomes
and Risk of Treatments).
Am J Respir Crit Care Med.
1996;
154
959-967
- 274
Garcia-Aymerich J, Farrero E, Felez M A. et al .
Risk factors of readmission to hospital for a COPD exacerbation: a prospective study.
Thorax.
2003;
58
100-105
- 275
Puhan M A, Scharplatz M, Troosters T. et al .
Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission
and mortality - a systematic review.
Respir Res.
2005;
6
54
- 276
Man W D, Polkey M I, Donaldson N. et al .
Community pulmonary rehabilitation: a randomised controlled study.
BMJ.
2004;
329
1209
- 277
Schultz K, Bergmann K C, Kenn K. et al .
Effektivität der pneumologischen Anschluss-Rehabilitation (AHB): Ergebnisse einer
multizentrischen prospektiven Beobachtungsstudie.
Dtsch Med Wochenschr.
2006;
131
1793-1798
- 278 World Health Organization (WHO) .International Classification of Functioning,
Disability and Health (ICF). Geneva 2001: http://www.3.who.int/icf/icftemplate.cfm)
- 279 Richtlinien des Gemeinsamen Bundesausschusses über Leistungen zur medizinischen
Rehabilitation (Rehabilitations-Richtlinien) nach § 92 Abs. 1 Satz 2 Nr. 8 SGB V in
der Fassung vom 16. März 2004 (BAnz. S. 6769) vom 31. März 2004 in Kraft getreten
am 1. April 2004. 2004 (cited: 2005 Jul 14). Available from: http://www.aerzteblatt.de/v4/archiv/artiekl.asp?id
= 41 621)
- 280
Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. ACCP/AACVPR
Pulmonary Rehabilitation Guidelines Panel.
Chest.
1997;
112
1363-1396
- 281 Verband deutscher Rentenversicherungsträger (VDR), Reha-Kommission .Krankheitsspezifsiche
Konzepte. In: VDR, Reha-Kommission (eds). Kommission zur Weiterentwicklung der Rehabilitation
in der gesetzlichen Rentenversicherung.Abschlussberichte.Band III, Teilband 2 Frankfurt:
VDR 1991: 483-484, 326
- 282 Bundesversicherungsanstalt für Angestellte (BfA) .Leitlinien zur Rehabilitationsbedürftigkeit
bei Krankheiten der Atmungsorgane - für den Beratungsärztlichen Dienst der BfA. 2004
(cited: 2005 Aug 12). Available from: http://www.bfa.de/nn 5910/de/Inhalt/Publikationen/Sonstige/Infos
20f C3 BCr 20 C3 84r zte Dokumente/Reha-Bed C3 Bcrftigkeit 20 2F 20 Pneumologie.html)
- 283 Medizinischer Dienst der Spitzenverbände der Krankenkassen e. V. (MDS) .Begutachtungs-Richtlinien
Vorsorge und Rehabilitation vom 12. März 2001. 2001 (cited: 2005 Aug 12). Available
from: http://informed.-msd-ev.de/sindbad.nsf/0/1885f053c9a0c58500256a31005377e7?OpenDocument
- 284
Szczepanski R, Taube K, Junggeburth J. et al .
Ambulante wohnortnahe pneumologische Prävention und Rehabilitation bei obstruktiven
Atemwegserkrankungen - Stand, Perspektive und Forschungsbedarf.
Pneumologie.
1998;
52
476-482
- 285
Goldstein R S, Gort E H, Stubbing D. et al .
Randomized controlled trial of respiratory rehabilitation.
Lancet.
1994;
344
1394-1397
- 286
McGavin C R, Gapta S P, Lloyd E L. et al .
Physical rehabilitation for the chronic bronchitis. Results of a controlled trial
of exercises in the home.
Thorax.
1977;
32
307-311
- 287
Magnussen H, Goeckenjan G, Köhler D. et al .
Leitlinien zur Sauerstoff-Langzeit-Therapie.
Pneumologie.
2001;
55
454-464
- 288
Report of the Medical Research Council Working Party. Long-term domiciliary oxygen
in chronic cor pulmonale complicating chronic bronchitis and emphysema.
Lancet.
1981;
1
681-685
- 289
Nocturnal oxygen therapy trial group .
Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary
disease.
Ann Intern Med.
1980;
93
191-198
- 290
Weitzenblum E, Sautegeau A, Ehrhart M. et al .
Long-term oxygen therapy can reverse the progression of pulmonary hypertension in
patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1985;
131
493-498
- 291
Leach R M, Davidson A C, Chinn S. et al .
Portable liquid oxygen and exercise ability in severe respiratory disability.
Thorax.
1992;
47
78-789
- 292
Tarpy S P, Celli B R.
Long-term oxygen therapy.
N Engl J Med.
1995;
333
710-714
- 293
Pelletier Fleury N, Laone J L, Fleury B. et al .
The cost of treating COPD patients with long-term oxygen therapy in a French population.
Chest.
1996;
110
411-416
- 294
Heaney L G, McAllister D, MacMahon J.
Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines
cost effective?.
BMJ.
1999;
319
19-23
- 295
Donahoe M, Rogers R M.
Nutritional assessment and support in chronic pulmonary disease.
Clin Chest Med.
1990;
11
487-504
- 296
Köhler D, Criée C P, Raschke F.
Leitlinien zur häuslichen Sauerstoff- und Heimbeatmungstherapie.
Pneumologie.
1996;
50
927-931
- 297
Simmonds A K, Elliot M W.
Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive
and obstructive disorders.
Thorax.
1995;
50
604-609
- 298
Meecham Jones D J, Paul E A, Jones P W. et al .
Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone
in hypercapnic COPD.
Am J Respir Crit Care Med.
1995;
152
538-544
- 299
Consensus Conference .
Clinical indications for noninvasive positive pressure ventilation in chronic respiratory
failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. A consensus
conference report.
Chest.
1999;
116
521-534
- 300
Mehran R J, Deslauriers J.
Indications for surgery and patient work-up for bullectomie.
Chest Surg Clin N Am.
1995;
5
717-734
- 301
Hughes J A, Hutchison D M, MacArthur D CS. et al .
Long-term changes in lung function after surgical treatment of bullos emphysema in
smokers and exsmokers.
Thorax.
1986;
39
140
- 302
Cooper J D, Trulock E P, Triantafillou A N. et al .
Bilateral pneumonectomy (volume reduction) for chronic obstructive pulmonary disease.
J Thorac Cardiovasc Surg.
1995;
109
106-119
- 303
National Emphysema Treatment Trial Research Group .
A randomized trial comparing lung-volume reduction surgery with medical therapy for
severe emphysema.
N Engl J Med.
2003;
348
2059-2073
- 304
Crouch R, Fishman A P, Ries A L. et al .
The Effects of Pulmonary Rehabilitation in the National Emphysema Treatment Trial.
Chest.
2005;
128
3799-3809
- 305
Venuta F, Yim A PC, Wan I YP. et al .
Bronchoscopic Lung Volume Reduction for End-Stage Emphysema: Report on the First 98
Patients.
Chest.
2006;
129
518-526
- 306
Trulock E P, Edwards L B, Taylor D O. et al .
The registry of the International Society for Heart and Lung Transplantation: Twenty-first
Official Adult Lung and Heart-Lung Transplant Report.
J Heart Lung Transplant.
2005;
24
956-967
- 307 Deutsche Stiftung Organtransplantation (DSO) .Bericht über die Tätigkeit der Transplantationszentren
sowie die Organspende in der Bundesrepublik Deutschland. http://www.dso.de/pdf/berichte2005/Gesamt_Taetigkeitsbericht2005.pdf
- 308
Hosenpud J D, Bennett L E, Keck B M. et al .
Effects of diagnosis on survival benefit of lung transplantation for end-stage lung
disease.
Lancet.
1998;
3
24-27
- 309
Charman S C, Sharples L D, McNeil K D. et al .
Assessment of Survival Benefit After Lung Transplantation by Patient Diagnosis.
J Heart Lung Transplant.
2002;
21
226-232
- 310
Gottlieb J, Simon A, Welte T.
Lungentransplantation.
Pneumologe.
2005;
2
131-141
- 311
Machado M C, Krishnan J A, Buist S A. et al .
Sex differences in survival of oxygen-dependent patients with chronic obstructive
pulmonary disease.
Am J Respir Crit Care Med.
2006 Sep 1;
174 (5)
524-529
- 312
Orens J B, Estenne M, Arcasoy S. et al .
International Guideline for the selection of lung transplant candidates: 2006 Update
- A consensus report from the pulmonary scientific council of the international society
for heart and lung transplant.
J Heart Lung Transplant.
2006;
25
745-755
- 313
Meyer D M, Bennett L E, Novick R J. et al .
Single vs bilateral, sequential lung transplantation for end-stage emphysema: influence
of recipient age on survival and secondary end-points.
J Heart Lung Transplant.
2001 Sep;
20 (9)
935-941
- 314
Trulock E P, Edwards L B, Taylor D O. et al .
Registry of the International Society for Heart and Lung Transplantation: twenty-third
official adult lung and heart-lung transplantation report - 2006.
J Heart Lung Transplant.
2006;
25
880-892
- 315
Elkington H, White P, Addington-Hall J. et al .
The last year of life of COPD: a qualitative study of symptoms and services.
Respir Med.
2004;
98
439-445
- 316
Booth S, Wade R, Johnson M. et al .
The use of oxygen in the palliation of breathlessness. A report of the expert working
group of the Scientific Committee of the Association of Palliative Medicine.
Respir Med.
2004;
98
66-77
- 317
Jennings A L, Davies A N, Higgins J P. et al .
A systematic review of the use of opioids in the management of dyspnoea.
Thorax.
2002;
57
939-944
- 318
Steinkamp G, Dierkesmann R, Gillissen A. et al .
COPD und Psyche - ein Überblick.
Pneumologie.
2005;
59
819-830
- 319 World Health Organization .Cancer pain relief and palliative care - report of
a WHO expert committee. Genf: World Health Organization 1990
- 320
Anthonisen N R, Manfreda J, Warren C P. et al .
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med.
1987;
106
196-204
- 321
Regueiro C R, Hamel M B, Davis R B. et al .
A comparison of generalist and pulmonologist care for patients hospitalized with severe
chronic obstructive pulmonary disease: resource intensity, hospital costs and survival.
Am J Med.
1998;
105
366-372
- 322
Gibson P G, Wlodarczyk J H, Wilson A J. et al .
Severe exacerbations of chronic obstructive airways disease: health resource use in
general practice and hospital.
J Qual Clin Pract.
1998;
18
125-133
- 323
Mushlin A I, Black E R, Connolly C A. et al .
The necessary length of hospital stay for chronic pulmonary disease.
JAMA.
1991;
266
80-83
- 324
Connors A F, Dawson N V, Thomas C. et al .
Outcomes following acute exacerbation of severe chronic obstructive lung disease.
The SUPPORT investigators.
Am J Respir Crit Care Med.
1996;
154
959-967
- 325
Kong G K, Belman M J, Weingarten S.
Reducing length of stay for patients hospi-talized with exacerbation of COPD by using
a practice guideline.
Chest.
1997;
111
89-94
- 326
Fuso L, Incalzi R A, Pistelli R. et al .
Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive
pulmonary disease.
Am J Med.
1995;
98
272-277
- 327
Seneff M G, Wagner D P, Wagner R P. et al .
Hospital and 1-year survival of patients admitted to intensive care units with acute
exacerbation of chronic obstructive pulmonary disease.
JAMA.
1995;
274
1852-1857
- 328
MacFarlane J T, Colville A, Macfarlane R M. et al .
Prospective study of aetiology and outcome of adult lower-respiratory-tract infections
in the community.
Lancet.
1993;
341
511-514
- 329
Stockley R A, O'Brien C, Pye A. et al .
Relationship of sputum color to nature and outpatient management of acute exacerbations
of COPD.
Chest.
2000;
117
1638-1645
- 330
Seemungal T R, Harpen-Owen R, Bhownik A. et al .
Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and
stable chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
2001;
164
1618-1623
- 331
Anderson H R, Spix C, Medina S. et al .
Air pollution and daily admissions for chronic obstructive pulmonary disease in 6
European cities: results from the APHEA project.
Eur Respir J.
1997;
10
1064-1071
- 332
Emerman C L, Connors A F, Lukens T W. et al .
Relationship between arterial blood gases and spirometry in acute exacerbations of
chronic obstructive pulmonary disease.
Ann Emerg Med.
1989;
18
523-527
- 333
Emerman C L, Effron D, Lukens T W.
Spirometric criteria for hospital admission of patients with acute exacerbation of
COPD.
Chest.
1991;
99
595-599
- 334
Emerman C L, Lukes T W, Effron D.
Physician estimation of FEV1 in acute exacerbation of COPD.
Chest.
1994;
105
1709-1712
- 335
Emerman C L, Cydulka R K.
Use of peak expiratory flow rate in emergency depart- ment evaluation of acute exacerbation
of chronic obstructive pulmonary disease [see comments].
Ann Emerg Med.
1996;
27
159-163
- 336
Tillie-Leblond I, Marquette C H, Perez T. et al .
Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive
pulmonary disease: prevalence and risk factors.
Ann Intern Med.
2006;
144
930-936
- 337
Rice K L, Leatherman J W, Duane P G. et al .
Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A
controlled trial.
Ann Intern Med.
1987;
107
305-309
- 338
Barbera J A, Reyes A, Roca J. et al .
Effect of intravenously administered aminophylline on ventilation/perfusion inequality
during recovery from exacerbations of chronic obstructive pulmonary disease.
Am Rev Respir Dis.
1992;
145
1328-1333
- 339
Mahon J L, Laupacis A, Hodder R V. et al .
Theophylline for irreversible chronic airflow limitation: a randomized study comparing
n of 1 trials to standard practice.
Chest.
1999;
115
38-48
- 340
Loberes P, Ramis L, Montserrat J M. et al .
Effect of three different bronchodilators during an exacerbation of chronic obstructive
pulmonary disease.
Eur Respir J.
1988;
1
536-539
- 341
Emerman C L, Connors A F, Lukens T W. et al .
Theophylline concentrations in patients with acute exacerbation of COPD [see comments].
Am J Emerg Med.
1990;
8
289-292
- 342
Duffy N, Walker P, Diamantea F. et al .
Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations
of chronic obstruktive pulmonary disease: a prospective randomized controlled trial.
Thorax.
2005;
60
713-717
- 343
Christ-Crain M, Jaccard-Stolz D, Bingisser R. et al .
Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory
tract infections: cluster-randomised, single-blinded intervention trial.
Lancet.
2004;
363 (9409)
600-607
- 344
Nouira S, Marghli S, Belghith M. et al .
Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring
mechanical ventilation: a randomised placebo-controlled trial.
Lancet.
2001;
358
2020-2025
- 345
Worth H, Adam D, Handrick W. et al .
Prophylaxe und Therapie von bronchopulmonalen Infektionen. Empfehlungen der Deutschen
Atemwegsliga.
Pneumologie.
1998;
52
232-237
- 346
Welte T, Marre R, Suttorp N.
Kompetenznetzwerk „Ambulant Erworbene Pneumonie” (CAPNETZ). Related Articles, What
is new in the treatment of community-acquired pneumonia?.
Med Klin (Munich).
2006 Apr 15;
101 (4)
313-320
- 347
Arancibia F, Bauer T T, Ewig S. et al .
Community-acquired Pneumonia caused by gram-negative bacteria: Incidence and risk
and prognosis.
Arch Intern Med.
2002;
162 (16)
1849-1858
- 348
Thompson , WH , Nielson C P, Carvalho P. et al .
Controlled trial of oral prednisolone in outpatients with acute COPD exacerbation.
Am J Respir Crit Care Med.
1996;
154
407-412
- 349
Davies L, Angus R M, Calverley P M.
Oral corticosteroids in patients admitted to hospital with exacerbations of chronic
obstructive pulmonary disease: a prospective randomised controlled trial.
Lancet.
1999;
354
456-460
- 350
Niewoehner D E, Erbland M L, Deupree R H. et al .
Effect of systemic glucocorticoids on exacxerbations of chronic obstructive pulmonary
disease.
N Engl J Med.
1999;
340
1941-1947
- 351
Bach P B, Brown C, Gelfand S E. et al .
Management of acute exacerbations of chronic obstructive pulmonary disease: a summary
and appraisal of published evidence.
Ann Intern Med.
2001;
134
600-620
- 352
Rossi A, Gottfried S B, Zocci L. et al .
Respiratory mechanics in mechanically ventilated patients with respiratory failure.
J Appl Physiol.
1985;
58
1849-1858
- 353
Georgopoulos D, Rossi A, Moxham J.
Ventilatory support in chronic obstructive pulmonary disease.
Eur Respir Mon.
1998;
7
189-208
- 354
Bott J, Carroll M P, Conway J H. et al .
Randomized controlled trial of nasal ventilation in acute ventilatory failure due
to chronic obstructive airways disease.
Lancet.
1993;
341
1555-1557
- 355
Brochard L, Mancebo J, Wysocki M. et al .
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.
N Engl J Med.
1995;
33
817-822
- 356
Kramer N, Meyer T J, Meharg J. et al .
Randomized, prospective trial of noninvasive positive pressure ventilation in acute
respiratory failure.
Am J Respir Crit Care Med.
1995;
151
1799-1806
- 357
Barbeacute F, Togores B, Rubi M. et al .
Noninvasive ventilatory support does not facilitate recovery from acute respiratory
failure in chronic obstructive pulmonary disease.
Eur Respir J.
1996;
9
1240-1245
- 358
Plant P K, Owen J L, Elliott M W.
Early use of non-invasive ventilation (NIV) for acute exacerbations of COPD on general
respiratory wards: a multicenter randomized controlled trial.
Lancet.
2000;
355
1931-1935
- 359
Nava S, Ambrosino N, Clini E. et al .
Noninvasive mechanical ventilation in the weaning of patients with respiratory failure
due to chronic obstructive pulmonary disease. A randomized, controlled trial.
Ann Intern Med.
1998;
128
721-728
- 360
Stoller J K, Lange P A.
Inpatient management of chronic obstructive pulmonary disease.
Respir Care Clin N Am.
1998;
4
425-438
- 361
Friedman M, Serby C W, Menjoge S S. et al .
Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared
with ipratropium alone and albuterol alone in COPD.
Chest.
1999;
115
635-641
- 362 Morgan W KG, Reger R B. Chronic airflow limitation and occupation. In: Cherniack
NS (Hrsg). Chronic obstructive pulmonary disease. Philadelphia: Saunders 1991
- 363
Nowak D.
Berufsbedingte obstruktive Atemwegserkrankung (BK4301 und 4302) gutachterliche Anmerkungen
zum Krankheitsbegriff und zur MdE.
Arbeitsmed Sozialmed Umweltmed.
2000;
35
164-167
- 364 Morfeld P, Piekarski C. Chronische Bronchitis und Emphysem als Berufskrankheit
der Steinkohlenbergleute. Schrittenreiche Zentralblatt für Arbeitsmedizin Haefer 1998
- 365
Nowak D.
Informationen zur neuen Berufskrankheit 4111: „Chronische obstruktive Bronchitis oder
Emphysem von Bergleuten unter Tage im Steinkohlenbergbau bei Nachweis der Einwirkung
einer kumulativen Feinstaubdosis von in der Regel 100 [(mg/m3) Jahre]”.
Pneumologie.
1996;
50
652-654
- 366 Kroidl R F, Nowak D, Seysen U. Bewertung und Begutachtung in der Pneumologie. Thieme
1999
- 367 Bundesministerium für Arbeit und Sozialordnung .Anhaltspunkte für die Ärztliche
Gutachtertätigkeit im sozialen Entschädigungsrecht und nach dem Schwerbehindertengesetz. Köllen
1996
Prof. Dr. med. Claus Vogelmeier
Klinik für Innere Medizin mit Schwerpunkt Pneumologie, Universitätsklinikum Gießen
und Marburg, Standort Marburg
Baldingerstraße
35043 Marburg
eMail: Claus.Vogelmeier@med.uni-marburg.de
